Fulcrum Therapeutics reports Q2 EPS (28c), consensus (29c)

Reports Q2 revenue $0 vs. $80M last year. As of June 30, cash, cash equivalents, and marketable securities were $214.1M vs. $241.0M as of December 31, 2024. The decrease of $26.9M is primarily due to cash used to fund operating activities in 2025. Fulcrum now expects that its current cash, cash equivalents, and marketable securities will be sufficient to fund its operating requirements into 2028. “Fulcrum has made substantial progress this quarter, having reported very promising results from the 12 mg cohort of the PIONEER trial,” said Alex C. Sapir, Fulcrum’s President and Chief Executive Officer. “We believe that this data demonstrates that pociredir has the potential to increase fetal hemoglobin to levels that could ameliorate SCD symptomology and transform the standard of care with a once daily oral treatment option. We look forward to reporting the 20 mg data later this year and progressing pociredir into later-stage development.”